Optical Genome Mapping

Global Optical Genome Mapping Market to Reach US$615.2 Million by 2030

The global market for Optical Genome Mapping estimated at US$139.6 Million in the year 2024, is expected to reach US$615.2 Million by 2030, growing at a CAGR of 28.0% over the analysis period 2024-2030. Optical Genome Mapping Services, one of the segments analyzed in the report, is expected to record a 28.9% CAGR and reach US$332.6 Million by the end of the analysis period. Growth in the Optical Genome Mapping Consumables & Reagents segment is estimated at 29.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$36.7 Million While China is Forecast to Grow at 26.5% CAGR

The Optical Genome Mapping market in the U.S. is estimated at US$36.7 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$92.9 Million by the year 2030 trailing a CAGR of 26.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 25.7% and 24.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 19.3% CAGR.

Global Optical Genome Mapping Market – Key Trends & Drivers Summarized

Why Is Optical Genome Mapping Disrupting Conventional Genomic Analysis?

Optical Genome Mapping (OGM) is emerging as a transformative force in genomic research and diagnostics, offering unprecedented resolution and accuracy in identifying structural variations (SVs) that are often missed by traditional sequencing technologies. While next-generation sequencing (NGS) has revolutionized genomics, it remains limited in detecting large-scale genomic rearrangements such as insertions, deletions, inversions, and translocations—areas where OGM excels. By utilizing ultra-long DNA molecules and imaging them in nanochannel arrays, OGM allows for real-time visualization of structural features across the entire genome without amplification or fragmentation. This capability is proving especially valuable in complex genetic disorders, hematological malignancies, solid tumors, and rare diseases, where understanding structural anomalies is critical for diagnosis and treatment planning. The growing need for comprehensive genomic profiling in personalized medicine, coupled with the demand for cost-effective and scalable solutions, is pushing academic institutions, clinical laboratories, and biotech companies to adopt OGM as a complementary or even primary tool. Its ability to integrate seamlessly with existing bioinformatics pipelines while offering insights that sequencing alone cannot provide is reshaping research workflows and expanding the utility of genomic data in translational and clinical applications.

How Are Technological Advances Enhancing the Performance and Accessibility of OGM?

The Optical Genome Mapping landscape is being rapidly reshaped by significant technological advancements that are making the platform more robust, user-friendly, and accessible across a broader range of applications. Improvements in nanochannel chip design and automated sample preparation are reducing hands-on time and increasing throughput, making OGM more practical for both high-volume clinical labs and academic research centers. The integration of AI and machine learning algorithms is enhancing the accuracy of structural variant calling and interpretation, minimizing human error and allowing for more reliable diagnostics. At the same time, cloud-based platforms for data analysis are simplifying collaboration between researchers and clinicians, enabling secure, real-time access to genomic insights. Miniaturization and portability efforts are also underway, with the goal of making OGM platforms suitable for decentralized and point-of-care environments. The ability to analyze ultra-high molecular weight DNA from various sample types—blood, bone marrow, solid tissue—without complex processing is expanding the method’s utility. Moreover, advancements in fluorescent labeling chemistries and optical detection are improving signal clarity, allowing for more precise mapping of structural elements across large genomes. As these innovations continue, they are not only lowering the barriers to adoption but also setting new standards in speed, scalability, and sensitivity for genomic analysis.

What End-Use Sectors Are Driving Demand and Expanding Application Frontiers?

The demand for Optical Genome Mapping is accelerating across a diverse set of end-use sectors, each leveraging the technology for distinct yet overlapping purposes. In clinical diagnostics, hematology and oncology are the most active domains, with OGM being used to uncover structural variants associated with leukemias, lymphomas, and solid tumors—many of which are undetectable through conventional karyotyping or chromosomal microarrays. In reproductive genetics, OGM is gaining traction for pre- and post-natal diagnostics of chromosomal abnormalities such as aneuploidies and copy number variations. Academic research institutions and genome centers are also adopting OGM for population studies, evolutionary biology, and functional genomics, due to its ability to uncover complex genomic architectures and gene regulatory networks. In the biopharmaceutical sector, OGM is being integrated into drug discovery pipelines, especially in biomarker identification and characterization of genetic instability in engineered cell lines. Agricultural genomics is another emerging area, where OGM is used to map plant genomes for crop improvement and trait selection. These broad and expanding use cases are driving demand for versatile OGM platforms that can operate across different sample types and data analysis environments. Furthermore, collaborations between technology providers and healthcare institutions are catalyzing validation studies and clinical adoption, pushing the market toward widespread acceptance.

What Forces Are Powering the Growth of the Optical Genome Mapping Market?

The growth in the Optical Genome Mapping market is driven by several factors related to technological evolution, end-user demands, and shifts in genomic research and diagnostic priorities. The growing need for high-resolution structural variant detection, particularly in oncology and rare disease diagnostics, is pushing laboratories to integrate OGM into their workflows. The limitations of short-read sequencing in identifying large-scale genomic alterations are creating a complementary demand for OGM, especially in cases where comprehensive genome structural profiling is essential. Advancements in automated instrumentation, improved nanochannel array designs, and scalable data analysis platforms are making OGM more user-friendly and operationally efficient. Increasing funding for genomic medicine and precision oncology, especially from government and private healthcare initiatives, is expanding the customer base among hospitals and specialty labs. The integration of OGM with multi-omics approaches and bioinformatics ecosystems is creating opportunities for end-to-end, systems-level insights in both research and clinical domains. Rising awareness among clinicians and geneticists about the unique value of OGM in solving previously undiagnosable cases is accelerating adoption. In emerging markets, the push for improved rare disease detection and cost-effective cancer diagnostics is encouraging investment in non-sequencing-based genomic tools. These cumulative drivers are establishing Optical Genome Mapping as a critical enabler in the next era of precision diagnostics and genomic discovery.

SCOPE OF STUDY:

The report analyzes the Optical Genome Mapping market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Product (Optical Genome Mapping Services, Optical Genome Mapping Consumables & Reagents, Optical Genome Mapping Software, Optical Genome Mapping Instruments); Technique (Structural Variant Detection Technique, Genome Assembly Technique, Microbial Strain Typing Technique, Other Techniques); Application (Research Application, Diagnostics Application); End-Use (Academic Research Institutes End-Use, Hospitals & Clinical Laboratories End-Use, Biotechnology & Pharmaceutical Companies End-Use)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 42 Featured) -

• Agilent Technologies Inc.
• Bionano Genomics
• Bio-Rad Laboratories Inc.
• Cerba Research
• Genohub Inc.
• Hamilton Company
• Hofkens Lab
• Illumina Inc.
• INRAE (French Plant Genomic Resources Center)
• MedGenome
• Nabsys
• NanoString Technologies
• Nucleome Informatics
• OpGen
• Oxford Nanopore Technologies
• PacBio (Pacific Biosciences)
• PerkinElmer Genomics
• Praxis Genomics, LLC
• QIAGEN N.V.
• Source BioScience

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.